Chimeric cell therapy - Dystrogen Therapeutics
Alternative Names: TRIMERA; Trimera -Dystrogen TherapeuticsLatest Information Update: 28 Sep 2025
At a glance
- Originator Dystrogen Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sarcopenia
- Discontinued Sickle cell anaemia
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for research development in Sarcopenia in USA (Parenteral)
- 25 Aug 2021 Discontinued - Preclinical for Sickle cell anaemia in USA (Parenteral), prior to August 2021 (Dystrogen Therapeutics pipeline, August 2021)
- 25 Aug 2021 Early research in Sarcopenia in USA (Parenteral), prior to August 2021 (Dystrogen Therapeutics pipeline, August 2021)